MyMD Pharmaceuticals, Inc. MYMD Stock News (” MyMD” or “the Firm”), a clinical phase pharmaceutical company committed to extending healthy lifespan, today introduced that the first patient has actually been enlisted in the Firm’s Phase 2 clinical trial of lead candidate MYMD-1, a dental immune regulator medicine, as a treatment for delaying aging and also increasing healthy life expectancy.
The main endpoint for the Stage 2 double-blind, placebo-controlled professional test is to achieve a reduction in the distributing degrees of (TNF-α), lump necrosis factor receptor I (TNFRI) and IL-6. TNF-α and also IL-6 are the healthy proteins in the body that cause inflammation as well as aid trigger the procedure of aging. The secondary steps of the test will be the security, tolerability, as well as pharmacokinetics in this populace of people.
” In a Stage 1 scientific test of MYMD-1, we showed the drug’s statistically considerable effectiveness in minimizing levels of TNF-α, a key player in causing pathological aging, in the blood. The FDA has authorized TNF-α reduction as the primary endpoint for our Phase 2 research, which our company believe positions us well for an effective Stage 2 end result,” said Chris Chapman, M.D., Head Of State, Director and Principal Medical Officer of MyMD. “The initiation of client enrollment in this study advances our objective to slow the aging procedure, avoid loss of muscle mass cells in aging, limitation frailty, and extend healthy lifespan.”
MyMD has actually specified that there are no FDA-approved medicines for treating aging disorders and prolonging healthy lifespan humans, a market expected to be a minimum of $600 billion by 20251 according to a major financial investment financial institution. TNF-α blockers are the most proposed medicines by earnings, a worldwide market of roughly $40 billion per year,2 and also, according to Nature Aging journal,3 a slowdown in maturing that would raise life expectancy by one year deserves $38 trillion as well as by 10 years deserves $367 trillion.
In addition to aging, MYMD-1’s distinctive activity in managing the immune system and also dealing with persistent inflammation is being created for the therapy of autoimmune disease, including rheumatoid joint inflammation (RA), numerous sclerosis (MS), diabetic issues, and inflammatory bowel disease.
” We plan to start writing protocols for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The increasing frequency of rheumatoid arthritis and also other autoimmune and also inflammatory conditions are driving demand for TNF inhibitors like MYMD-1, and our team believe our orally carried out drug with extremely low poisoning would certainly be turbulent to the $60 billion market for RA if approved by the FDA for this sign.”
Rheumatoid joint inflammation affects roughly 40 million people around the world.4.
Initially developed for autoimmune diseases, MYMD-1’s key function is to slow the aging procedure, avoid sarcopenia and frailty, and prolong healthy and balanced lifespan. Due to the fact that it can cross the blood-brain obstacle and get to the central nerves (CNS), MYMD-1 is also positioned to be a feasible treatment for brain-related conditions. Its system of activity and effectiveness in diseases consisting of several sclerosis (MS) and thyroiditis have actually been researched with partnerships with a number of scholastic organizations. MYMD-1 is also showing promise in pre-clinical researches as a potential treatment for blog post- COVID-19 complications and also as an anti-fibrotic as well as anti-proliferation therapeutic.
MYMD-1 has shown performance in pre-clinical studies in regulating the immune system by doing as a selective prevention of lump death factor-alpha (TNF-α), a chauffeur of persistent inflammation. Unlike other therapies, MYMD-1 has been displayed in these pre-clinical research studies to precisely obstruct TNF-α when it becomes overactivated in autoimmune diseases and also cytokine storms, but not block it from doing its typical task of being an initial responder to any regular kind of modest infection. MYMD-1’s ease of dental application is another differentiator contrasted to currently readily available TNF-α blockers, every one of which call for delivery by injection or infusion. No approved TNF prevention has actually ever before been dosed orally. Furthermore, the drug is not immunosuppressive and has actually not been revealed to cause the severe side effects common with standard therapies that treat swelling.
Regarding MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific stage pharmaceutical company devoted to expanding healthy life expectancy, is focused on establishing 2 unique restorative platforms that treat the causes of condition instead of only attending to the signs and symptoms. MYMD-1 is a drug system based on a clinical phase small molecule that regulates the body immune system to manage TNF-α, which drives persistent inflammation, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to postpone aging, boost long life, and deal with autoimmune diseases as well as COVID-19- connected anxiety. The Firm’s 2nd drug system, Supera-CBD, is being established to treat chronic discomfort, dependency and also epilepsy. Supera-CBD is an unique synthetic derivative of cannabidiol (CBD) and also is being created to attend to and also improve upon the swiftly expanding CBD market, that includes both FDA accepted medicines as well as CBD products not currently regulated as drugs. For more information, go to www.mymd.com.